BiotechTube

Roflumilast Cream 0.05% + Vehicle Cream

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis Eczema

Conditions

Atopic Dermatitis Eczema

Trial Timeline

Apr 7, 2021 → Jun 1, 2023

NCT ID
NCT04845620

About Roflumilast Cream 0.05% + Vehicle Cream

Roflumilast Cream 0.05% + Vehicle Cream is a phase 3 stage product being developed by Arcutis Biotherapeutics for Atopic Dermatitis Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT04845620. Target conditions include Atopic Dermatitis Eczema.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04845620Phase 3Completed
NCT03916081Phase 2Completed

Competing Products

20 competing products in Atopic Dermatitis Eczema

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52

Other Products from Arcutis Biotherapeutics

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Phase 3
72
Roflumilast Cream + Vehicle creamPhase 3
72
Roflumilast Foam 0.3% + Vehicle FoamPhase 3
72
Roflumilast Foam + Vehicle FoamPhase 3
72
ARQ-151 0.3% cream + ARQ-151 vehicle creamPhase 3
72